

United States Patent and Trademark Office

UNITED STATES DEPARTMEN United States Patent and Tradem Address: COMMISSIONER FOR PAT P.O. Box 1450 Alexandria, Virginia 22313 1450 www.uspto.gov

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR CONFIRMATION NO. APPLICATION NO. FILING DATE 07/14/2003 TPP 31402A 10/617,850 Amar Lulla **EXAMINER** 24257 7590 05/03/2004 PATEL, NIHIR B STEVENS DAVIS MILLER & MOSHER, LLP 1615 L STREET, NW PAPER NUMBER ART UNIT **SUITE 850** WASHINGTON, DC 20036 3743

DATE MAILED: 05/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	(C)
Office Action Summany	10/617,850	LULLA ET AL.	CV
Office Action Summary	Examiner	Art Unit	
	Nihir Patel	3743	
Th MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).			
Status			
1) Responsive to communication(s) filed on			
2a) This action is FINAL . 2b) ⊠ Th	nis action is non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4) ☐ Claim(s) is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement.			
Application Papers			
9) The specification is objected to by the Examiner.			
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.			
Applicant may not request that any objection to the			-D 4 404(-I)
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 			
Attachment(s)			
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ☐ Interview Summary Paper No(s)/Mail D		
Notice of Draftsperson's Patent Drawing Review (P10-946) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date			D-152)
C. Datast and Tondomedi Office			

DETAILED ACTION

Specification

1. The disclosure is objected to because of the following informalities: In the specifications the applicant refers to convergent end 105 to be placed in the mouth of the patient as well as being connected to the aerosol medicament reservoir see page 4 of the specifications.

Appropriate correction is required.

Claim Objections

2. Claim 2 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. In the independent claim 1, the applicant states that the chamber is made of polyamide whereas in dependent claim 2 the applicant states that the chamber is made of an antistatic plastic material.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 10 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by O'Callaghan Patent No. WO 93/11817. Referring to claims 10, O'Callaghan discloses improvements in the administration of aerosol compounds that does provide a non-metallic

Application/Control Number: 10/617,850

Art Unit: 3743

antistatic space device for the inhalation of a particulate medicament in a volatile medium (see page 4).

Referring to claim 11, O'Callaghan discloses an apparatus wherein there is substantially little or no deposit of medicament on the inside of the device (see page 4).

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 2, 5, 6, 8, 9, 12, and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over O'Callaghan et al. Patent No. WO 93/11817.

O'Callaghan clearly states that "the interior surface would be most conveniently coated with a more permanent anti-static coating such as a coating or film of plastic material having anti-static properties" and since polyamide has anti-static properties it would have been obvious to modify O'Callaghan invention by coating the interior surface with polyamide in order to reduce the tendency for particles of the drug to be attracted to the surfaces.

Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over O'Callaghan Patent No. WO 93/11817 in view of Kriesel US Patent No. 6,030,363.

O'Callaghan discloses the applicant's invention as claimed with the exception of providing locking means to lock the two members together in assembled condition.

Kriesel discloses a medicament dispenser that does provide locking means. Therefore it would be obvious to modify Callaghan's invention by providing locking means to lock the two

Application/Control Number: 10/617,850 Page 4

Art Unit: 3743

members together in assembled condition in order to prevent the two members from becoming loose.

Conclusion

5. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communication from the examiner should be directed to Nihir Patel whose telephone number is (703) 306-3463. The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm. If attempts to reach the examiner by telephone are unsuccessful the examiner supervisor Henry Bennett can be reached at (703) 308-0101.

NP April 29th, 2004

Group 3700